Scarica l'app Stockscreener
17.11
0.71%
0.12
Dopo l'orario di chiusura:
16.93
-0.18
-1.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$16.99
Aprire:
$17.04
Volume 24 ore:
7.05M
Relative Volume:
1.09
Capitalizzazione di mercato:
$11.68B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
3.0283
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+6.14%
1M Prestazione:
+20.66%
6M Prestazione:
+70.76%
1 anno Prestazione:
+42.94%
Intervallo 1D:
$16.89
$17.27
Intervallo di 1 settimana:
$15.90
$17.27
Portata 52W:
$8.73
$17.27
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
17.11 | 11.20B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Ltd. stock prediction for this week2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
Using Ichimoku Cloud for Roivant Sciences Ltd. technicalsPortfolio Performance Report & Verified Chart Pattern Signals - newser.com
Roivant Sciences stock hits all-time high at 16.8 USD By Investing.com - Investing.com South Africa
Roivant Sciences stock hits all-time high at 16.8 USD - Investing.com India
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
Roivant Sciences president Venker sells $2m in shares By Investing.com - Investing.com South Africa
Roivant Sciences president Venker sells $2m in shares - Investing.com
Positive Phase 3 Data and Analyst Support Could Be a Game Changer for Roivant Sciences (ROIV) - simplywall.st
A Look at Roivant Sciences’s Valuation Following Positive Phase 3 Result for Brepocitinib - Sahm
Top chart patterns to watch in Roivant Sciences Ltd.Trade Performance Summary & Community Verified Watchlist Alerts - newser.com
Evaluating Roivant Sciences Ltd. with trendline analysisQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Key metrics from Roivant Sciences Ltd.’s quarterly dataQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
What MACD and RSI say about Roivant Sciences Ltd.Trade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: An Attractive 24.97% Upside in the Biotech Arena - DirectorsTalk Interviews
How sentiment analysis helps forecast Roivant Sciences Ltd.Market Trend Report & Fast Moving Stock Trade Plans - newser.com
Using Bollinger Bands to evaluate Roivant Sciences Ltd.July 2025 Trends & Community Consensus Picks - newser.com
Is a relief rally coming for Roivant Sciences Ltd. holders2025 Bull vs Bear & Daily Oversold Bounce Ideas - newser.com
Combining machine learning predictions for Roivant Sciences Ltd.July 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Price action breakdown for Roivant Sciences Ltd.2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Will earnings trigger a reversal in Roivant Sciences Ltd.Weekly Market Summary & Safe Entry Zone Identification - newser.com
Eric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
What earnings revisions data tells us about Roivant Sciences Ltd.Bear Alert & Comprehensive Market Scan Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Hits New 52-Week High at $16.19, Up 52.84% - Markets Mojo
Roivant Sciences Hits New 52-Week High at $16.79, Surges 53.69% - Markets Mojo
Roivant Sciences’ president Venker sells $10.7m in shares - Investing.com
Valeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences’ president Venker sells $10.7m in shares By Investing.com - Investing.com Canada
Roivant Sciences Rises on Nasdaq Composite with Strong Momentum - Kalkine Media
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighShould You Buy? - MarketBeat
Can you recover from losses in Roivant Sciences Ltd.2025 Price Action Summary & High Return Trade Guides - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockWeekly Trading Summary & Community Driven Trade Alerts - newser.com
Will Roivant Sciences Ltd. (87S) stock outperform value peersRisk Management & Consistent Profit Alerts - newser.com
Why Roivant Sciences (ROIV) Is Up 6.6% After Positive Phase 3 Brepocitinib Results and SEC Filing - simplywall.st
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsTrade Risk Report & Fast Entry High Yield Stock Tips - newser.com
Will Roivant Sciences Ltd. continue its uptrendWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Pattern recognition hints at Roivant Sciences Ltd. upsideMarket Growth Report & Safe Capital Growth Tips - newser.com
Is Roivant Sciences Ltd. stock reversal real or fakeM&A Rumor & High Win Rate Trade Tips - newser.com
Can Roivant Sciences Ltd. (87S) stock double in coming yearsJuly 2025 Breakouts & Fast Entry Momentum Alerts - newser.com
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints - Insider Monkey
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades - Yahoo Finance
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Oct 09 '25 |
Option Exercise |
15.85 |
104,940 |
1,663,299 |
1,609,899 |
| Venker Eric | President & Immunovant CEO |
Oct 13 '25 |
Option Exercise |
15.85 |
20,727 |
328,523 |
1,525,686 |
| Venker Eric | President & Immunovant CEO |
Oct 09 '25 |
Sale |
16.30 |
104,940 |
1,710,522 |
1,504,959 |
| Venker Eric | President & Immunovant CEO |
Oct 13 '25 |
Sale |
16.25 |
20,727 |
336,814 |
1,504,959 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):